Rufinamide | CGP 33101 | Antiepileptic Agent | AmBeed-信号通路专用抑制剂

首页 / / / / Rufinamide

卢非酰胺 /Rufinamide {[allProObj[0].p_purity_real_show]}

货号：A193932 同义名： CGP 33101;E 2080

Rufinamide, an antiepileptic agent, is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).

Rufinamide 化学结构
CAS号：106308-44-5

Rufinamide 3D分子结构
CAS号：106308-44-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Rufinamide 纯度/质量文件产品仅供科研

货号：A193932 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell Host Microbe, 2024. Ambeed. [ A163338 ]; • Cancer Res., 2024. Ambeed. [ A295334 ]; • J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]; • J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]; • JBC, 2024, 107935. Ambeed. [ A194396 ]; 更多 >

钠通道亚型比较

产品名称	Sodium Channel ↓ ↑	纯度
Tolperisone HCl	✔	99%
Lamotrigine	✔	98%
Vinpocetine	✔	98%
Zonisamide	✔	98%
Dronedarone Hydrochloride	✔	95%
Procainamide hydrochloride	✔	99%
Bupivacaine HCl	✔	99+%
Benzocaine	✔	98%
Carbamazepine	++ Sodium channel, IC50: 131 μM	98%
Ibutilide fumarate	✔	99%+
Dibucaine HCl	✔	99+%
Mexiletine HCl	✔	99%
Phenytoin	✔	99+%
Camostat Mesylate	+++ epithelial sodium channel (ENaC), IC50: 50 nM	99%+
Levobupivacaine	✔	97+%
Oxcarbazepine	+ sodium channel, IC50: 160 μM	98%
Ambroxol		98+%
Primidone	✔	99%
Propafenone	✔	99%
A-803467	++++ Na(V1.8) channel, IC50: 8 nM	99%+
Rufinamide	✔	99%
Phenytoin sodium	✔	98%
Proparacaine Hydrochloride	+ Voltage-gated sodium channel, ED50: 3.4 mM	98+%
Riluzole	✔	97%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Rufinamide 生物活性

靶点	Sodium Channel
描述	Rufinamide is an antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).

Rufinamide 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02205931	Epilepsy	Phase 4	Recruiting	June 2019	United Kingdom ... 展开 >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom, B4 6NH Contact: Shakti Agrawal, MBBS 0044 1213338149 shakti.agrawal@bch.nhs.uk Principal Investigator: Shakti Agrawal, MBBS Bristol Royal Hospital for Children Recruiting Bristol, United Kingdom, BS2 8AE Contact: Andrew Mallick, FRCPCH Principal Investigator: Andrew Mallick Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Alasdair Parker, MA 0044 1223 245151 alasdair.parker@addenbrookes.nhs.uk Principal Investigator: Alasdair Parker, MA Lancashire Teaching Hospitals NHS Foundation Trust Recruiting Lancashire, United Kingdom Contact: Helen Basu Helen.Basu@lthtr.nhs.uk Principal Investigator: Helen Basu Leeds Teaching Hospital Recruiting Leeds, United Kingdom, LS1 3EX Contact: Helen McCullagh, RCPCH 0044 113 243 2799 h.mccullagh@nhs.net Principal Investigator: Helen McCullagh, RCPCH Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom, L12 2AP Contact: Rachel Kneen, BMBS 0044 151 2525163 rachel.kneen@liverpool.ac.uk Principal Investigator: Rachel Kneen, BMBS Great Ormond Street Hospital Recruiting London, United Kingdom, WC1N 3JH Contact: Christin Eltze, MD Res 0044 207 405 9200 ext 5438 christin.eltze@gosh.nhs.uk Principal Investigator: Christin Eltze, MD Res St George's University Hospitals NHS Foundation Trust Recruiting London, United Kingdom Contact: Penny Fallon Penny.Fallon@stgeorges.nhs.uk Principal Investigator: Penny Fallon Royal Manchester Children's Hospital Recruiting Manchester, United Kingdom, M13 0JE Contact: Tim Martland, RCPCH 0044 161 276 1234 timothy.martland@cmft.nhs.uk Principal Investigator: Tim Martland, RCPCH The Newcastle Upon Tyne Hospitals NHS Foundation Trust Recruiting Newcastle upon Tyne, United Kingdom Contact: Anita Devlin Anita.Devlin@nuth.nhs.uk Principal Investigator: Anita Devlin Sheffield Children's NHS Foundation Trust Recruiting Sheffield, United Kingdom Contact: Archana Desurkar Archana.Desurkar@sch.nhs.uk Principal Investigator: Archana Desurkar 收起 <<
NCT00552526	Epilepsy Ment... 展开 >>al Retardation 收起 <<	Phase 4	Unknown	December 2013	Norway ... 展开 >> SSE, Nevrological dep. , Rikshospitalet University hospital Oslo, Norway 收起 <<
NCT01212458	-		Completed	-	Switzerland ... 展开 >> University Hospital Zurich, Institut of Anaesthesiology Zurich, ZH, Switzerland, 8091 收起 <<

Rufinamide 参考文献

[1]Wright HM, Chen AV, et al. Pharmacokinetics of oral rufinamide in dogs. J Vet Pharmacol Ther. 2012 Dec;35(6):529-33.

[2]Williams ET, Carlson JE, et al. Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.

Rufinamide 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

4.20mL

0.84mL

0.42mL

20.99mL

4.20mL

2.10mL

41.98mL

8.40mL

4.20mL

Rufinamide 技术信息

CAS号	106308-44-5
分子式	C₁₀H₈F₂N₄O
分子量	238.194

别名	CGP 33101;E 2080;Inovelon.;Brand name: BANZEL;RUF 331
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Room temperature

溶解度

DMSO: 50 mg/mL(209.91 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

IP 4% DMSO+2% Tween80+40% PEG300+water 1 mg/mL clear

PO 0.5% CMC-Na 62 mg/mL suspension

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02205931	Epilepsy	Phase 4	Recruiting	June 2019	United Kingdom ... 展开 >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom, B4 6NH Contact: Shakti Agrawal, MBBS 0044 1213338149 shakti.agrawal@bch.nhs.uk Principal Investigator: Shakti Agrawal, MBBS Bristol Royal Hospital for Children Recruiting Bristol, United Kingdom, BS2 8AE Contact: Andrew Mallick, FRCPCH Principal Investigator: Andrew Mallick Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Alasdair Parker, MA 0044 1223 245151 alasdair.parker@addenbrookes.nhs.uk Principal Investigator: Alasdair Parker, MA Lancashire Teaching Hospitals NHS Foundation Trust Recruiting Lancashire, United Kingdom Contact: Helen Basu Helen.Basu@lthtr.nhs.uk Principal Investigator: Helen Basu Leeds Teaching Hospital Recruiting Leeds, United Kingdom, LS1 3EX Contact: Helen McCullagh, RCPCH 0044 113 243 2799 h.mccullagh@nhs.net Principal Investigator: Helen McCullagh, RCPCH Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom, L12 2AP Contact: Rachel Kneen, BMBS 0044 151 2525163 rachel.kneen@liverpool.ac.uk Principal Investigator: Rachel Kneen, BMBS Great Ormond Street Hospital Recruiting London, United Kingdom, WC1N 3JH Contact: Christin Eltze, MD Res 0044 207 405 9200 ext 5438 christin.eltze@gosh.nhs.uk Principal Investigator: Christin Eltze, MD Res St George's University Hospitals NHS Foundation Trust Recruiting London, United Kingdom Contact: Penny Fallon Penny.Fallon@stgeorges.nhs.uk Principal Investigator: Penny Fallon Royal Manchester Children's Hospital Recruiting Manchester, United Kingdom, M13 0JE Contact: Tim Martland, RCPCH 0044 161 276 1234 timothy.martland@cmft.nhs.uk Principal Investigator: Tim Martland, RCPCH The Newcastle Upon Tyne Hospitals NHS Foundation Trust Recruiting Newcastle upon Tyne, United Kingdom Contact: Anita Devlin Anita.Devlin@nuth.nhs.uk Principal Investigator: Anita Devlin Sheffield Children's NHS Foundation Trust Recruiting Sheffield, United Kingdom Contact: Archana Desurkar Archana.Desurkar@sch.nhs.uk Principal Investigator: Archana Desurkar 收起 <<
NCT00552526	Epilepsy Ment... 展开 >>al Retardation 收起 <<	Phase 4	Unknown	December 2013	Norway ... 展开 >> SSE, Nevrological dep. , Rikshospitalet University hospital Oslo, Norway 收起 <<
NCT01212458	-		Completed	-	Switzerland ... 展开 >> University Hospital Zurich, Institut of Anaesthesiology Zurich, ZH, Switzerland, 8091 收起 <<
NCT01146951	Lennox-Gastaut Syndrome	Phase 3	Completed	-	Japan ... 展开 >> Nagoya-shi, Aichi, Japan Matsuyama-shi, Ehime, Japan Fukuoka-shi, Fukuoka, Japan Hiroshima-shi, Hiroshima, Japan Sapporo-shi, Hokkaido, Japan Kobe-shi, Hyogo, Japan Yokohama-shi, Kanagawa, Japan Goshi-shi, Kumamoto, Japan Iwamuma-shi, Miyagi, Japan Omura-shi, Nagasaki, Japan Nara-shi, Nara, Japan Niigata-shi, Niigata, Japan Yufu-shi, Oita, Japan Okayama-shi, Okayama, Japan Neyagawa-shi, Osaka, Japan Osaka-shi, Osaka, Japan Suita-shi, Osaka, Japan Moriya-shi, Shiga, Japan Shizuoka-shi, Shizuoka, Japan Kodaira-shi, Tokyo, Japan Kokubunji-shi, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Toyoma-shi, Toyama, Japan 收起 <<
NCT01146951	-		Completed	-	-
NCT00595231	Generalized Anxiety Disorder	Phase 2	Completed	-	United States, Georgia ... 展开 >> Carmen Research Atlanta, Georgia, United States, 30080 United States, Ohio Midwest Clinical Research Center Dayton, Ohio, United States, 45408 收起 <<
NCT01991041	-		Completed	-	-
NCT02175173	-		Recruiting	July 1, 2019	Japan ... 展开 >> Recruiting Osaka, Japan Recruiting Tokyo, Japan 收起 <<
NCT00334958	Epilepsy	Phase 3	Completed	-	-
NCT00448539	-		Completed	-	-
NCT01405053	Lennox-Gastaut Syndrome	Phase 3	Completed	-	United States, District of Col... 展开 >>umbia Washington, District of Columbia, United States United States, Florida Tampa, Florida, United States Wellington, Florida, United States United States, Kentucky Lexington, Kentucky, United States United States, Ohio Akron, Ohio, United States Columbus, Ohio, United States United States, Texas San Antonio, Texas, United States United States, Virginia Norfolk, Virginia, United States Canada, Alberta Edmonton, Alberta, Canada France Bron, France Marseille, France Paris, France Greece Pendeli Athens, Greece Thessaloniki, Greece Italy Mantua, MN, Italy Calambrone, PI, Italy Pavia, PV, Italy Roma, RM, Italy Poland Elblag, Poland Gdansk, Poland Kielce, Poland Poznan, Poland 收起 <<
NCT02095899	Peripheral Nerve Injuries ... 展开 >> Pain 收起 <<	Phase 2	Withdrawn(Poor study patient r... 展开 >>ecruitment) 收起 <<	-	Switzerland ... 展开 >> University Hospital Zurich, Institut of Anaesthesiology Zurich, ZH, Switzerland, 8091 收起 <<
NCT02332174	Seizures	Phase 1	Completed	-	-
NCT00334958	-		Completed	-	-
NCT00448539	Refractory Partial Onset Seizu... 展开 >>res 收起 <<	Phase 3	Completed	-	-

卢非酰胺 /Rufinamide {[allProObj[0].p_purity_real_show]}

Rufinamide 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Rufinamide 质控信息

Rufinamide 生物活性

Rufinamide 临床研究

Rufinamide 参考文献

Rufinamide 实验方案

Rufinamide 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

卢非酰胺 /Rufinamide {[allProObj[0].p_purity_real_show]}

Rufinamide 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Rufinamide 质控信息

Rufinamide 生物活性

Rufinamide 临床研究

Rufinamide 参考文献

Rufinamide 实验方案

Rufinamide 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Rufinamide 纯度/质量文件产品仅供科研